Please assess the completion status of the following clinical trial:

Trial Title: Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ST segment elevation acute myocardial infarction~* 20% \< angiographic diameter stenosis \< 50% on a not previously revascularized native coronary artery~* Statin naïve~Exclusion Criteria:~* Pharmacologic lipid lowering treatment before index hospitalization~* Atrial fibrillation, not well rate-controlled~* Ventricle frequency variation with more than a factor 2 over 1 minute~* Unconscious patients~* Total cholesterol \> 7.0 mmol/l~* History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins) including rosuvastatin~* Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have a positive serum pregnancy test (a serum-human chorionic gonadotrophin \[Beta-HCG\] analysis)~* History of malignancy (unless a documented disease free period exceeding 5-years is present) with the exception of basal cell or squamous cell carcinoma of the skin, or in the case of a study designed to investigate antineoplastic properties of rosuvastatin. Women with a history of cervical dysplasia would be permitted to enter the study provided they had 3 consecutive clear Papanicolaou (Pap) smears~* Uncontrolled hypothyroidism (TSH \> 1.5xULN)~* Abnormal LFT's~* History of alcohol or drug abuse within the last 5 years (this may affect compliance)~* Current active liver disease (ALT/SGPT \>2xULN or severe hepatic impairment (to protect patient safety as directed on the labels of currently approved statins)~* Unexplained creatine kinase (CK \> 3xULN) (To protect patient safety) (will be increased at baseline because of acute ST segment elevation myocardial infarction a few days before enrolment)~* Serum creatinine \>176mmol/L (2.0mg/dL) (unless the protocol specifically aims to investigate a chronic renal disease population)~* Participation in another investigational drug study less than 4 weeks before enrolment in the study, or according to subjects local ethics committee requirements where a larger period is stipulated (to avoid potential misinterpretation of overlapping adverse events)~* Treatments with cyclosporine~* Treatment with gemfibrozil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin 5mg (Type: ACTIVE_COMPARATOR): Rosuvastatin 5mg/day for one year
- Rosuvaststin 40mg (Type: ACTIVE_COMPARATOR): Rosuvastatin 40mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).